Stock AnalizCRISPR Therapeutics AG CRSP
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2016 · data as of November 13, 2026
CRISPR Therapeutics AG (CRSP) is a healthcare company listed in the US with a market value of about $4.1B. In the twelve months to September 30, 2026 it had revenue of $25M and net income of -$456M, a net margin of -1812.1%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 37% a year, a 5-year average ROIC of -14%.
Score: 1.0 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25M | $4M | $37M | $371M | $1M | $915M | $719000 | $290M | $3M | $41M | $5M |
| Net income | -$456M | -$582M | -$366M | -$154M | -$650M | $378M | -$349M | $67M | -$165M | -$68M | -$23M |
| Free cash flow | -$377M | -$346M | -$145M | -$270M | -$533M | $457M | -$257M | $50M | -$99M | -$78M | -$56M |
| EPS (diluted) | $-4.72 | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | $-1.89 |
| Net margin | -1812.1% | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% |
| ROIC | — | -24.7% | -17.1% | -8.3% | -31.7% | 14.2% | -16.2% | 4.7% | -32.0% | -27.2% | -23.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 19 analysts is $85.42, 102% above the current price; targets range from $44.00 to $291.00; the consensus rating is “Buy”; expected EPS is $-4.53 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does CRISPR Therapeutics pay a dividend?
Not currently.
Is CRISPR Therapeutics a good stock to buy?
We do not give buy or sell advice. CRISPR Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.